Ranibizumab is a recombinant humanized IgG1 monoclonal antibody fragment that binds to and inhibits vascular endothelial growth factor A
The move strengthens GBL’s clinical-stage presence in the United States
The combination also outperformed chemotherapy on another important secondary endpoint
Patients with BRCA mutations often face aggressive disease and poor prognosis
Clinical trial enrollment has long been a bottleneck in drug development
The approval of Augmentin XR, granted to USAntibiotics, directly supports the CNPV program’s goals
Subscribe To Our Newsletter & Stay Updated
